Jonathan Stutters Selected Research

Atrophy

3/2022

Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonathan Stutters Research Topics

Disease

6	Multiple Sclerosis 10/2023 - 01/2018
2	Chronic Progressive Multiple Sclerosis 01/2020 - 01/2018
1	Gliosis 10/2023
1	Inflammation (Inflammations) 03/2022
1	Atrophy 03/2022
1	Hypothyroidism 01/2021
1	Neutropenia 01/2021
1	Exanthema (Rash) 01/2021
1	Relapsing-Remitting Multiple Sclerosis 01/2021
1	Obesity 01/2020
1	Thrombosis (Thrombus) 01/2020
1	Heart Diseases (Heart Disease) 01/2020
1	Sudden Death 01/2020
1	Lung Neoplasms (Lung Cancer) 01/2020
1	Disease Progression 01/2018

Drug/Important Bio-Agent (IBA)

2	Riluzole FDA LinkGeneric 10/2023 - 01/2020
2	Fluoxetine (Prozac)FDA LinkGeneric 10/2023 - 01/2020
2	Bexarotene (LGD1069)FDA Link 10/2022 - 01/2021
2	Neuroprotective AgentsIBA 01/2020 - 01/2018
1	Inositol (Myoinositol)IBA 10/2023
1	N-acetylaspartate (N-acetyl aspartate)IBA 10/2023
1	Choline (Choline Chloride)IBA 10/2023
1	CreatineIBA 10/2023
1	temelimabIBA 03/2022
1	Retinoid X Receptors (Retinoid X Receptor)IBA 01/2021
1	Amiloride (Midamor)FDA LinkGeneric 01/2020

Therapy/Procedure

1	Therapeutics 01/2018